HK Stock Market Move | XPENG-W (09868) opened down more than 8%. The loss in the second quarter expanded nearly 1.8 times year-on-year, and the guidance for the third quarter is below market expectations.
XPeng Motors-W (09868) opened down over 8%. As of the time of writing, it has dropped 8.18%, trading at HKD 43.78, with a transaction volume of HKD 23.8939 million.
XPENG-W (09868) opened down over 8%, and as of the time of writing, it has dropped 8.18% to HKD 43.78, with a transaction value of HKD 23.8939 million.
In news, on August 24, Xpeng released its performance announcement for the first half of 2026. During the reporting period, the company achieved a total revenue of RMB 32.78 billion, a year-on-year decrease of 3.8%; net loss was RMB 3.12 billion, an increase of 173.35% year-on-year. In the second quarter alone, Xpeng's total revenue was RMB 19.74 billion, a year-on-year increase of 8% and a quarter-on-quarter increase of 51.5%; however, the net loss was RMB 1.34 billion, nearly 1.8 times larger year-on-year, but narrowed by 25.1% quarter-on-quarter.
In the first half of this year, Xpeng's total delivery volume was 165,977 vehicles, a year-on-year decrease of 15.8%. Looking ahead, Xpeng expects delivery volume for the third quarter to be between 115,000 and 121,000 vehicles, a year-on-year change of approximately -0.87% to 4.30%, while the market estimate is around 147,000 vehicles; revenue guidance is RMB 21.7 billion to RMB 23.4 billion, a year-on-year increase of about 6.5% to 14.8%, also significantly lower than the market estimate of RMB 27.26 billion.
Related Articles

HK Stock Market Move | LEADS BIOLABS-B (09887) rose over 5% in early trading as Vili Xin's Phase II clinical trial for frontline treatment of ESCC enters the expansion stage.
.png)
ABBISKO-B (02256) Mid-Year Report Observation: MNC Continues to "Place Orders," Accelerating the Realization of Innovative Platform Value

HK Stock Market Move | KB LAMINATES (01888) surged over 8% in early trading, with its mid-term net profit soaring by 209%. The profit in July was approximately HKD 1.1 billion.
HK Stock Market Move | LEADS BIOLABS-B (09887) rose over 5% in early trading as Vili Xin's Phase II clinical trial for frontline treatment of ESCC enters the expansion stage.

ABBISKO-B (02256) Mid-Year Report Observation: MNC Continues to "Place Orders," Accelerating the Realization of Innovative Platform Value
.png)
HK Stock Market Move | KB LAMINATES (01888) surged over 8% in early trading, with its mid-term net profit soaring by 209%. The profit in July was approximately HKD 1.1 billion.

RECOMMEND





